Hurvitz concludes that these results validate the PAM pathway as a key molecular driver in HR+/HER2– advanced breast cancer ...

Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and ...

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential ...

argenx (NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across multiple late-stage pipeline programs, while newly appointed CEO Karen ...

Vepdegestrant, first PROTAC in breast cancer, improved PFS vs fulvestrant in ESR1-mutant ER+/HER2− disease after endocrine therapy plus CDK4/6i (5.0 vs 2.1 months; HR 0.57). Decitabine/cedazuridine ...

"ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies" was originally created and published by Clinical ...

A second-line triplet regimen involving the novel intravenous drug gedatolisib significantly reduced the risk of progression ...

Phase 3 data on sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive ...

Our computer's lone five-star play of the night is Josh Hart to fall short of his 3-point line at plus-odds, with a +24.98% EV edge. The New York Knicks SG has missed the Over in six of his last 10, ...

Combining standard transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen improved ...

Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...